Collectively, these findings underscore the critical role of molecular diagnostics (including Pan‐Trk IHC and fusion detection) in identifying TPM3‐NTRK1 fusion‐positive mesenchymal tumors across diverse sites and age groups and strongly support the therapeutic relevance of TRK inhibitors for this molecularly defined subset of sarcomas [67]. This evidence concerns the gene TPM3 and mesenchymal cell neoplasm.